The use of a small molecule SHIP-1 inhibitor demonstrated that catalytically active SHIP-1 is required for the survival of multiple myeloma cells (Brooks et al., 2010) and that therefore, in certain cases, SHIP-1 actually supports cancer cell survival. Here, INPP5D is linked to plasma cell myeloma.